2 patents currently held
12 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2030. from the record
Of the 12 now held by other companies, 12 name Lxo Ireland Designated Activity Company Lxo US Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Nov 2030
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Feb 2034 · High confidence
Also notable
Ends Feb 2038 · High confidence
Use of Amisulpride as an Anti-Emetic
US 9,084,765
Cited by 17 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
now held by Lxo Ireland Designated Activity Company; Lxo US, Inc.
Rescue Treatment of Post Operative Nausea and Vomiting
US 11,357,753
Cited by 4 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
now held by Lxo Ireland Designated Activity Company; Lxo US, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 6, 2027The maintenance fee for Use of Bethaneciol for Treatment of Xerostomia (US 9,149,454) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Use of Bethaneciol for Treatment of Xerostomia | 2 in force | to Nov 2030 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,149,454 | Use of Bethaneciol for Treatment of Xerostomia In force · High confidence | In force | High confidence | |
| US 10,137,084 | Use of Bethanechol for Treatment of Xerostomia In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 12 patents in force now held by others · 2 patents ended · 3 applications pending · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed